Bariatric Surgery Significantly Outperforms GLP-1 Medications for Weight Loss
Published: 2026/01/08 04:10:34
new research indicates that bariatric surgery leads to substantially greater weight loss compared to popular injectable medications like semaglutide and tirzepatide. A study presented at the American society for Metabolic and Bariatric Surgery (ASMBS) 2025 Annual Scientific Meeting found that individuals undergoing sleeve gastrectomy or Roux-en-Y gastric bypass lost approximately five times more weight over two years than those using GLP-1 receptor agonists.
Real-World Weight Loss results
researchers at NYU Langone Health and NYC Health + Hospitals analyzed data from over 51,000 patients. The results showed that bariatric surgery patients lost an average of 58 pounds, equating to 24% of total body weight, over a two-year period. in contrast, patients prescribed GLP-1 medications for at least six months experienced an average weight loss of onyl 12 pounds (4.7% of total body weight). even with continuous GLP-1 therapy for a year,average weight loss only reached 7% [2].
Clinical Trial vs. Real-World Effectiveness
The study highlights a notable discrepancy between the weight loss observed in controlled clinical trials and the results seen in everyday clinical practice. While clinical trials suggest GLP-1s can lead to 15% to 21% weight loss, the real-world data indicates considerably lower outcomes. Researchers attribute this to factors like medication discontinuation rates, which can be as high as 70% within one year [1].
Study Methodology
The research team analyzed electronic medical record data from patients treated between 2018 and 2024.Participants had a body mass index (BMI) of 35 or higher and either underwent bariatric surgery (sleeve gastrectomy or Roux-en-Y gastric bypass) or were prescribed injectable semaglutide or tirzepatide. The analysis adjusted for factors such as age, BMI, and co-existing health conditions using average treatment effect weighting. The study received support from the National Institutes of Health (NIH) [3].
Future Research and Considerations
Researchers plan to investigate strategies to optimize GLP-1 outcomes, identify which patients are most suitable for bariatric surgery versus medication, and assess the impact of treatment costs on success rates. They aim to understand how healthcare providers can best support patients in achieving their weight loss goals.
GLP-1 Medication Usage and Adherence
GLP-1 drugs have gained considerable attention, with approximately 12% of Americans having tried them and 6% currently using them. However, maintaining long-term adherence remains a challenge. Studies show that over half of patients discontinue GLP-1 therapy within the first year,and this rate increases to over 72% by two years.
Bariatric Surgery Utilization
Despite its proven effectiveness, bariatric surgery remains underutilized. in 2023, over 270,000 metabolic and bariatric procedures were performed, representing only about 1% of individuals who meet the BMI criteria for the surgery [2].
Expert Outlook
“While both approaches can lead to weight loss, metabolic and bariatric surgery is demonstrably more effective and provides more durable results,” stated Ann M. Rogers,MD,FACS,FASMBS,President of the ASMBS. “Individuals who experience insufficient weight loss with GLP-1s or struggle with treatment adherence due to side effects or cost should consider bariatric surgery as a viable option, potentially even in combination with medication.”
The Ongoing Challenge of Obesity
According to the U.S. Centers for disease Control and prevention (CDC), 40.3% of adults in the United States are affected by obesity, and 9.4% are considered severely obese. Obesity is linked to a range of health problems,including impaired immune function,chronic inflammation,cardiovascular disease,stroke,type 2 diabetes,and certain cancers.
*Semaglutide is the active ingredient in Ozempic and Wegovy, while tirzepatide is found in Zepbound and Mounjaro.